Davide Capodanno Shares FITTER Trial: Evolocumab Shows No Added Short-Term Benefit in Acute Coronary Syndrome
Davide Capodanno, professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”In the double-blind, randomized FITTER trial, 150 patients with acute coronary syndrome and relevant non-culprit lesions received evolocumab or placebo for 12 weeks in addition to high-intensity statin therapy.
PCSK9 inhibition did not produce additional short-term improvements in plaque lipid content, plaque volume, or coronary physiology.”
Read the full article here.
Find the editorial here.
Article: Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial
Authors: Frans B. Mensink, Jonathan Los, Mohamed M. Reda Morsy, Rohit M. Oemrawsingh, Clemens von Birgelen, Alexander J.J. Ijsselmuiden, Martijn Meuwissen, Jin M. Cheng, Diederik F. van Wijk, Pieter C. Smits, Valeria Paradies, Dirk J. van Wijk, Himanshu Rai, Tim J.F. ten Cate, Cyril Camaro, Peter Damman, Lokien X. van Nunen1, Aukelien C. Dimitriu-Leen, Marleen H. van Wely, Aysun Cetinyurek-Yavuz, Robert A. Byrne, Niels van Royen, Robert-Jan M. van Geuns
Stay informed on all science in Hematology with Hemostasis Today.
-
Aug 18, 2025, 23:54TNF-α–Mediated Platelet Dysfunction: Inflammation, Autophagy Inhibition, and Thrombosis Risk
-
Aug 18, 2025, 23:53Radiotherapy and VTE Risk: Insights from Marc Carrier and Colleagues
-
Aug 18, 2025, 23:52PCI and Bleeding Risk: Shea E. Hogan Reviews Aspirin-Free Approaches
-
Aug 18, 2025, 23:49Ahmed Kotb: HHT Management—Choosing the Right Therapy?
-
Aug 18, 2025, 23:48Pulmonary Embolism Management: Experts Share Valuable Insights on Endovascular Today
-
Aug 18, 2025, 23:54Davide Capodanno Shares FITTER Trial: Evolocumab Shows No Added Short-Term Benefit in Acute Coronary Syndrome
-
Aug 18, 2025, 11:04Albert Farrugia: The Past, Present and Future of Blood Plasma Fractionation
-
Aug 18, 2025, 09:57Eugene Yang: When Should Prevention of Atherosclerosis Begin?
-
Aug 18, 2025, 09:34SIREN Study: Important Insights Hypertension and Low Vegetable Consumption Double Stroke Odds
-
Aug 18, 2025, 09:03Genetic Insights: FVIII A3 Variants and Inhibitor Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada